http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Oua?ssi, Mehdi,Studer, Anne-Sophie,Mege, Diane,Thuny, Franck,Boiron, Laurence,Loundou, Anderson,Pirr?, Nicolas,Hamed, Samy,Frasconi, Cecilia,Habib, Gilbert,Fournier, Pierre-Edouard,Collart, Fr?deric,S Potamitis Press 2014 Anticancer research Vol.34 No.1
<P>Association between streptococcal endocarditis and gastrointestinal disease has been well-documented in the literature. However oncological impact of this complicated presentation has not yet been reported. We have conducted to our knowledgethe first case-control study on this subject.</P>
Barlesi, F.,Scherpereel, A.,Gorbunova, V.,Gervais, R.,Vikströ,m, A.,Chouaid, C.,Chella, A.,Kim, J. H.,Ahn, M. J.,Reck, M.,Pazzola, A.,Kim, H. T.,Aerts, J. G,Morando, C.,Loundou, A.,Groen, H. J. M. Oxford University Press 2014 Annals of oncology Vol.25 No.5
<P>The randomized, phase III AVAPERL trial evaluated the safety and efficacy of bevacizumab maintenance with or without pemetrexed in nonsquamous non–small cell lung cancer (nsNSCLC). Progression-free survival (PFS) was significantly prolonged with bevacizumab–pemetrexed. At a median follow-up of 14.8 months, OS events occurred in 58% of all patients. OS was numerically longer with bevacizumab–pemetrexed versus bevacizumab when measured from randomization (17.1 versus 13.2 months, HR, 0.87 [0.63–1.21]; P=0.29). Second-line therapy was administered in 77% and 70% of patients in the bevacizumab and bevacizumab–pemetrexed arms, respectively.</P>